It has been reported that activation of Nrf2 inhibited NAFLD and NASH through upregulating heme oxygenase-1 (HO-1) /NAD(P)H:quinone oxidoreductase 1 (NQO1)/glutathione S-transferase (GST), then promoted hepatocellular carcinoma by competing with Keap1 or through FGFR4–GSK3β signal pathway [23]. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatohepatitis.